Journal of Applied Physiology Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

J Appl Physiol 73: 2069-2073, 1992;
8750-7587/92 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mullol, J.
Right arrow Articles by Kaliner, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mullol, J.
Right arrow Articles by Kaliner, M. A.

Journal of Applied Physiology, Vol 73, Issue 5 2069-2073, Copyright © 1992 by American Physiological Society

ARTICLES

M1 and M3 muscarinic antagonists inhibit human nasal glandular secretion in vitro

J. Mullol, J. N. Baraniuk, C. Logun, M. Merida, J. Hausfeld, J. H. Shelhamer and M. A. Kaliner
Servei de Pneumologia i Allergia Respiratoria, Hospital Clinic, Barcelona, Spain.

Mucus glycoproteins (MGP) are high-molecular-weight glycoconjugates that are released from submucosal glands and epithelial goblet cells in the respiratory tract. Muscarinic receptors have an important role in the regulation of human nasal glandular secretion and mucus production, but it is not known which of the five muscarinic receptor subtypes are involved. The effect of nonselective and M1-, M2-, and M3-selective muscarinic antagonists on methacholine (MCh)-induced MGP secretion from human nasal mucosal explants was tested in vitro. MGP was assayed by enzyme-linked immunosorbent assay using a specific anti-MGP monoclonal antibody (7F10). MCh (100 microM) induced MGP secretion up to 127% compared with controls. MCh-induced MGP release was significantly inhibited by atropine (100 microM), the M, receptor antagonist pirenzepine (10-100 microM), and the M3 receptor antagonist 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP; 1-100 microM). 4-DAMP significantly inhibited MCh-induced MGP release at a lower concentration (1 microM) than pirenzepine (10 microM). The M2 receptor antagonists AF-DX 116 and gallamine (both at 100 microM) had no effect. No antagonist alone had a significant effect on MGP release. These results indicate that the M1 and M3 muscarinic receptor subtypes regulate MGP secretion from human nasal mucosa and suggest that the M3 receptor has the predominant effect.


This article has been cited by other articles:


Home page
 Proc Am Thorac SocHome page
B. J. Proskocil and A. D. Fryer
{beta}2-Agonist and Anticholinergic Drugs in the Treatment of Lung Disease
Proceedings of the ATS, November 1, 2005; 2(4): 305 - 310.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. N. Baraniuk, K. N. Petrie, U. Le, C.-F. Tai, Y.-J. Park, A. Yuta, M. Ali, C. J. VandenBussche, and B. Nelson
Neuropathology in Rhinosinusitis
Am. J. Respir. Crit. Care Med., January 1, 2005; 171(1): 5 - 11.
[Abstract] [Full Text] [PDF]

Home page
 JDRHome page
V. Thuong Nguyen, L.L. Hall, G. Gallacher, A. Ndoye, D.L. Jolkovsky, R.J. Webber, R. Buchli, and S.A. Grando
Choline Acetyltransferase, Acetylcholinesterase, and Nicotinic Acetylcholine Receptors of Human Gingival and Esophageal Epithelia
Journal of Dental Research, April 1, 2000; 79(4): 939 - 949.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online